Biotech Values

[iwfal]

EOLS - Here are the pictures from the paper. I've now done more than a 'quick check' for *one* of the Jeuveau 40 unit curves (the Investigator curve - but not the Patient curve).

For the investigator curves given below (left curve) it is, as best it's possible for me to measure, identical to the 23Q3 version of the same (investigator) curve out through 120 days (which is also the median - about 15 days later than 20 unit dose of Jeuveau, and about 30 days later than botox dose and 23 days earlier than Sakura 1). But from there on the formally published paper is meaningfully lower than the 23Q3 Jeuveau 40 unit dose curve, although still above the Sakura 1 dose from day 190 on.

Essentially: Sakura 1 has a better median by about 23 days (but beware the caveats below), but the last quarter of the population seems to be about the same for Daxxy and Jeuveau 40 unit dose

And the caveats:

a) The comparison to Sakura is a cross trial comparison... inherently noisy. See next point.
b) The Jeuveau 40 unit population is a meaningfully tougher population in which to get no-or-mild-lines than either of the Sakura populations (Jeuveau is 70% Severe, Sakura closer to only 40% Severe).